Mar 02, 2011 11:49 EST Halo Genomics
Feb 17, 2011 03:00 EST Attana AB The summit includes presentations on ensuring successful drug discovery, stimulating innovation and creating partnerships.
Jan 19, 2011 09:39 EST Attana AB Attana's Oscar Norberg participated in and presented at the Pacifichem conference in Hawaii at the end of last year. The presentation concerned photo-click immobilization on quartz crystal microbalance sensors for selective carbohydrate−protein interaction analyses, and received a lot of interest.
Dec 22, 2010 03:00 EST Attana AB Attana is one of the sponsor companies at the upcoming marcus evans Discovery Summit 2011 in Cannes, France, 21-23 March. Prior to the event marcus evans and Aastrup discuss in this interview the role biologics can play in speeding up drug discovery and subsequent stages.
Dec 21, 2010 05:51 EST Attana AB Attana appears in Dresdner Neueste Nachrichten, a regional German newspaper in association with the inauguration of the new “B CUBE” research labs of the Technische Universität Dresden. The new research labs are part of a large regional German investment for scientific research and innovative technologies. The Attana 200 appears here as one of B CUBE’s innovative biosensor technologies
Nov 17, 2010 08:50 EST Halo Genomics
Oct 12, 2010 04:17 EDT Olink Bioscience Olink Bioscience is hosting the 1st Duolink User Meeting in Uppsala, Sweden, October 18-19
Oct 11, 2010 09:27 EDT Olink Bioscience Olink Bioscience launches two new Detection Reagents; Duolink® II Detection Reagents Far Red and Green.
Sep 29, 2010 07:15 EDT Attana AB Sveriges Radio Ekot has interviewed Attana's Chief Financial Officer Jesper Isaksson. The story covers how the increased value of the Swedish krona against the Euro and the US dollar influences Swedish exporting and importing companies. Jesper gives a brief input on Attana's approach.
Sep 22, 2010 09:34 EDT Attana AB Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.